Infección por el VIH

1 Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med 2011; 1: 006841. PubMed
2 Hemelaar J, Gouws E, Ghys PD, Osmanov Sfor the WHO-UNAIDS Network for HIV Isolation and Characterisation. Global trends in molecular epidemiology of HIV-1 during 2000—2007. AIDS 2011; 25: 679-689. PubMed
3 UNAIDS. Report on the global AIDS epidemic 2013. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf. (accessed Nov 9, 2013).
4 WHO. Global update on HIV treatment 2013: results, impact and opportunities. June 2013. Geneva, Switzerland: World Health Organization, 2013.
5 Zaidi J, Grapsa E, Tanser F, Newell ML, Barnighausen T. Dramatic increases in HIV prevalence after scale-up of antiretroviral treatment: a longitudinal population-based HIV surveillance study in rural kwazulu-natal. AIDS 2013; 27: 2301-2305. PubMed
6 Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 2010; 376: 285-301. Summary | Full Text | PDF(316KB) | PubMed
7 Birrell PJ, Gill ON, Delpech VC, et al. HIV incidence in men who have sex with men in England and Wales 2001—10: a nationwide population study. Lancet Infect Dis 2013; 13: 313-318. Summary | Full Text | PDF(272KB) | PubMed
8 Mayer KH, Mimiaga MJ. Past as prologue: the refractory and evolving HIV epidemic among men who have sex with men. Clin Infect Dis 2011; 52: 1371-1373. PubMed
9 Beyrer C, Sullivan P, Sanchez J, et al. The global HIV epidemics in MSM: time to act. AIDS 2013; 27: 2665-2678. PubMed
10 UNAIDS. 2013 progress report on the global plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive. http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2013/20130625_progress_global_plan_en.pdf. (accessed Jan 30, 2014).
11 Ortblad KF, Lozano R, Murray CJ. The burden of HIV: insights from the GBD 2010. AIDS 2013; 27: 2003-2017. PubMed
12 Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996—2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50: 1387-1396. PubMed
13 Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173: 614-622. PubMed
14 Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet 2011; 377: 1198-1209. Summary | Full Text | PDF(620KB) | PubMed
15 Glaziou P, Falzon D, Floyd K, Raviglione M. Global epidemiology of tuberculosis. Semin Respir Crit Care Med 2013; 34: 3-16. PubMed
16 Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005; 191: 150-158. PubMed
17 Holmes CB, Wood R, Badri M, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006; 42: 464-469. PubMed
18 Cohen T, Murray M, Wallengren K, Alvarez GG, Samuel EY, Wilson D. The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study. PLoS Med 2010; 7: e1000296. PubMed
19 Quinn TC, Wawer MJ, Sewankambo N, et althe Rakai Project Study Group. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 342: 921-929. PubMed
20 Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 Infection. N Engl J Med 2011; 364: 1943-1954. PubMed
21 Lingappa JR, Hughes JP, Wang RS, et althe Partners in Prevention HSV/HIV Transmission Study Team. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One 2010; 5: e12598. PubMed
22 Baeten JM, Kahle E, Lingappa JR, et althe Partners in Prevention HSV/HIV Transmission Study Team. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med 2011; 3: 77ra29. PubMed
23 Røttingen JA, Cameron DW, Garnett GP. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known?. Sex Transm Dis 2001; 28: 579-597. PubMed
24 Glynn JR, Biraro S, Weiss HA. Herpes simplex virus type 2: a key role in HIV incidence. AIDS 2009; 23: 1595-1598. PubMed
25 Atashili J, Poole C, Ndumbe PM, Adimora AA, Smith JS. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS 2008; 22: 1493-1501. PubMed
26 Mugo NR, Heffron R, Donnell D, et althe Partners in Prevention HSV/HIV Transmission Study Team. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS 2011; 25: 1887-1895. PubMed
27 Baggaley RF, White RG, Boily MC. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol 2010; 39: 1048-1063. PubMed
28 Weiss HA, Quigley MA, Hayes RJ. Male circumcision and risk of HIV infection in sub-Saharan Africa: a systematic review and meta-analysis. AIDS 2000; 14: 2361-2370. PubMed
29 Polis CB, Curtis KM. Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence. Lancet Infect Dis 2013; 13: 797-808. Summary | Full Text | PDF(507KB) | PubMed
30 Butler AR, Smith JA, Polis CB, Gregson S, Stanton D, Hallett TB. Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk. AIDS 2013; 27: 105-113. PubMed
31 Tanser F, Bärnighausen T, Hund L, Garnett GP, McGrath N, Newell ML. Effect of concurrent sexual partnerships on rate of new HIV infections in a high-prevalence, rural South African population: a cohort study. Lancet 2011; 378: 247-255. Summary | Full Text | PDF(535KB) | PubMed
32 Epstein H, Morris M. Concurrent partnerships and HIV: an inconvenient truth. J Int AIDS Soc 2011; 14: 13. PubMed
33 Hughes JP, Baeten JM, Lingappa JR, et althe Partners in Prevention HSV/HIV Transmission Study Team. Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis 2012; 205: 358-365. PubMed
34 Crawford ND, Vlahov D. Progress in HIV reduction and prevention among injection and noninjection drug users. J Acquir Immune Defic Syndr 2010; 55 (suppl 2): S84-S87. PubMed
35 Jewkes RK, Dunkle K, Nduna M, Shai N. Intimate partner violence, relationship power inequity, and incidence of HIV infection in young women in South Africa: a cohort study. Lancet 2010; 376: 41-48. Summary | Full Text | PDF(150KB) | PubMed
36 Davidson's Principles and Practice of Medicine. In: Walker BR, Colledge NR, Ralston SH, Penman I, eds. . London, UK: Churchill Livingstone, 2014.
37 Liu Y, Liu H, Kim BO, et al. CD4-independent infection of astrocytes by human immunodeficiency virus type 1: requirement for the human mannose receptor. J Virol 2004; 78: 4120-4133. PubMed
38 Chen P, Chen BK, Mosoian A, et al. Virological synapses allow HIV-1 uptake and gene expression in renal tubular epithelial cells. J Am Soc Nephrol 2011; 22: 496-507. PubMed
39 Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 2003; 9: 1404-1407. PubMed
40 Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004; 427: 848-853. PubMed
41 Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451: 425-430. PubMed
42 Hrecka K, Hao C, Gierszewska M, et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011; 474: 658-661. PubMed
43 Laguette N, Sobhian B, Casartelli N, et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011; 474: 654-657. PubMed
44 Yan N, Regalado-Magdos AD, Stiggelbout B, Lee-Kirsch MA, Lieberman J. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat Immunol 2010; 11: 1005-1013. PubMed
45 Maertens G, Cherepanov P, Pluymers W, et al. LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J Biol Chem 2003; 278: 33528-33539. PubMed
46 Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008; 105: 7552-7557. PubMed
47 Parrish NF, Gao F, Li H, et al. Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci USA 2013; 110: 6626-6633. PubMed
48 Stacey AR, Norris PJ, Qin L, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009; 83: 3719-3733. PubMed
49 Goonetilleke N, Liu MK, Salazar-Gonzalez JF, et althe CHAVI Clinical Core B. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009; 206: 1253-1272. PubMed
50 Almeida JR, Price DA, Papagno L, et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 2007; 204: 2473-2485. PubMed
51 Ladell K, Hashimoto M, Iglesias MC, et al. A molecular basis for the control of preimmune escape variants by HIV-specific CD8+ T cells. Immunity 2013; 38: 425-436. PubMed
52 Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006; 12: 1198-1202. PubMed
53 Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003; 100: 4144-4149. PubMed
54 Walker LM, Huber M, Doores KJ, et althe Protocol G Principal Investigators. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011; 477: 466-470. PubMed
55 Klein F, Diskin R, Scheid JF, et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 2013; 153: 126-138. PubMed
56 Liao HX, Lynch R, Zhou T, et althe NISC Comparative Sequencing Program. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013; 496: 469-476. PubMed
57 Jardine J, Julien JP, Menis S, et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013; 340: 711-716. PubMed
58 Alter G, Heckerman D, Schneidewind A, et al. HIV-1 adaptation to NK-cell-mediated immune pressure. Nature 2011; 476: 96-100. PubMed
59 Cooper A, García M, Petrovas C, Yamamoto T, Koup RA, Nabel GJ. HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration. Nature 2013; 498: 376-379. PubMed
60 Mehandru S, Poles MA, Tenner-Racz K, et al. Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early human immunodeficiency virus type 1 infection. J Virol 2007; 81: 599-612. PubMed
61 Prendergast A, Prado JG, Kang YH, et al. HIV-1 infection is characterized by profound depletion of CD161+ Th17 cells and gradual decline in regulatory T cells. AIDS 2010; 24: 491-502. PubMed
62 Cosgrove C, Ussher JE, Rauch A, et al. Early and nonreversible decrease of CD161++ /MAIT cells in HIV infection. Blood 2013; 121: 951-961. PubMed
63 Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-1371. PubMed
64 Zeng M, Southern PJ, Reilly CS, et al. Lymphoid tissue damage in HIV-1 infection depletes naïve T cells and limits T cell reconstitution after antiretroviral therapy. PLoS Pathog 2012; 8: e1002437. PubMed
65 Lichtfuss GF, Hoy J, Rajasuriar R, Kramski M, Crowe SM, Lewin SR. Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. Biomarkers Med 2011; 5: 171-186. PubMed
66 Meier A, Chang JJ, Chan ES, et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med 2009; 15: 955-959. PubMed
67 Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS 2006; 20: 2275-2283. PubMed
68 Kuller LH, Tracy R, Belloso W, et althe INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: e203. PubMed
69 Hsue PY, Scherzer R, Hunt PW, et al. Carotid intima-media thickness progression in HIV-infected adults occurs preferentially at the carotid bifurcation and is predicted by inflammation. J Am Heart Assoc 2012; 1.
70 Marks MA, Rabkin CS, Engels EA, et al. Markers of microbial translocation and risk of AIDS-related lymphoma. AIDS 2013; 27: 469-474. PubMed
71 Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One 2008; 3: e2516. PubMed
72 Andrade BB, Hullsiek KH, Boulware DR, et althe INSIGHT Study Group. Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis viruses. J Infect Dis 2013; 207: 1379-1388. PubMed
73 Buzón MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16: 460-465. PubMed
74 Hunt PW, Martin JN, Sinclair E, et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis 2011; 203: 1474-1483. PubMed
75 Gonzalez VD, Falconer K, Blom KG, et al. High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J Virol 2009; 83: 11407-11411. PubMed
76 Rajasuriar R, Khoury G, Kamarulzaman A, French MA, Cameron PU, Lewin SR. Persistent immune activation in chronic HIV infection: do any interventions work?. AIDS 2013; 27: 1199-1208. PubMed
77 Tuboi SH, Brinkhof MW, Egger M, et al. Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. J Acquir Immune Defic Syndr 2007; 45: 52-59. PubMed
78 Rajasuriar R, Gouillou M, Spelman T, et al. Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database. PLoS One 2011; 6: e20713. PubMed
79 Helleberg M, Kronborg G, Larsen CS, et al. Causes of death among Danish HIV patients compared with population controls in the period 1995—2008. Infection 2012; 40: 627-634. PubMed
80 Abrams D, Lévy Y, Losso MH, et althe INSIGHT-ESPRIT Study Group, the SILCAAT Scientific Committee. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009; 361: 1548-1559. PubMed
81 Sereti I, Dunham RM, Spritzler J, et althe ACTG 5214 Study Team. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009; 113: 6304-6314. PubMed
82 Vandergeeten C, Fromentin R, DaFonseca S, et al. Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood 2013; 121: 4321-4329. PubMed
83 Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308: 387-402. PubMed
84 World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. June 2013. http://www.who.int/hiv/pub/guidelines/arv2013/download/en/index.html. (accessed Aug 30, 2013).
85 Sigaloff KC, Hamers RL, Wallis CL, et althe PharmAccess African Studies to Evaluate Resistance (PASER). Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr 2011; 58: 23-31. PubMed
86 Boyer S, March L, Kouanfack C, et althe Stratall ANRS 12110/ESTHER Study Group. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis. Lancet Infect Dis 2013; 13: 577-586. Summary | Full Text | PDF(228KB) | PubMed
87 Keiser O, Orrell C, Egger M, et althe Swiss HIV Cohort Study (SHCS) and the International Epidemiologic Databases to Evaluate AIDS in Southern Africa (IeDEA-SA). Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med 2008; 5: e148. PubMed
88 Boulle A, Schomaker M, May M, Egger M, Sterne JA. Mortality after starting ART in treatment-naïve adults in 3 continents: collaborative analysis of international epidemiologic databases to evaluate AIDS in southern Africa and ART cohort collaboration cohorts. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, Georgia; 2013.
89 Rodger AJ, Lodwick R, Schechter M, et althe INSIGHT SMART, ESPRIT Study Groups. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013; 27: 973-979. PubMed
90 Walker BD, Hirsch MS. Antiretroviral therapy in early HIV infection. N Engl J Med 2013; 368: 279-281. PubMed
91 Sabin CA, Cooper DA, Collins S, Schechter M. Rating evidence in treatment guidelines: a case example of when to initiate combination antiretroviral therapy (cART) in HIV-positive asymptomatic persons. AIDS 2013; 27: 1839-1846. PubMed
92 Kulkarni SP, Shah KR, Sarma KV, Mahajan AP. Clinical uncertainties, health service challenges, and ethical complexities of HIV “test-and-treat”: a systematic review. Am J Public Health 2013; 103: e14-e23. PubMed
93 Kranzer K, Govindasamy D, Ford N, Johnston V, Lawn SD. Quantifying and addressing losses along the continuum of care for people living with HIV infection in sub-Saharan Africa: a systematic review. J Int AIDS Soc 2012; 15: 17383. PubMed
94 Boulle A, Van Cutsem G, Hilderbrand K, et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 2010; 24: 563-572. PubMed
95 Centers for Disease Control and Prevention. Vital signs: HIV prevention through care and treatment — United States2011. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6047a4.htm. (accessed June 3, 2014).
96 Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS 2009; 23: 1035-1046. PubMed
97 World Health Organization. WHO HIV drug resistance report 2012. 2012.
98 Lawn SD, Meintjes G. Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy. Expert Rev Anti Infect Ther 2011; 9: 415-430. PubMed
99 Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger Mthe IeDEA Southern and Central Africa. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 251-261. Summary | Full Text | PDF(284KB) | PubMed
100 Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010; 24: 2381-2390. PubMed
101 Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5: 512-517. PubMed
102 Chun TW, Nickle DC, Justement JS, et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008; 197: 714-720. PubMed
103 Cusini A, Vernazza PL, Yerly S, et althe Swiss HIV Cohort Study. Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. J Acquir Immune Defic Syndr 2013; 62: 28-35. PubMed
104 Saleh S, Solomon A, Wightman F, Xhilaga M, Cameron PU, Lewin SR. CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood 2007; 110: 4161-4164. PubMed
105 Yang HC, Xing S, Shan L, et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest 2009; 119: 3473-3486. PubMed
106 Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15: 893-900. PubMed
107 Wightman F, Solomon A, Khoury G, et al. Both CD31(+) and CD31 naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. J Infect Dis 2010; 202: 1738-1748. PubMed
108 Ellery P, Sonza S, Paukovics G, et al. CD14lo/CD16hi monocytes are more permissive to HIV infection in vitro and may selectively harbour HIV-1 in patients on highly active antiretroviral therapy. 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco, CA; 2004. p. Abstract 426.
109 Gorry P, Purcell D, Howard J, McPhee D. Restricted HIV-1 infection of human astrocytes: potential role of nef in the regulation of virus replication. J Neurovirol 1998; 4: 377-386. PubMed
110 Van Lint C, Bouchat S, Marcello A. HIV-1 transcription and latency: an update. Retrovirology 2013; 10: 67. PubMed
111 Huang J, Wang F, Argyris E, et al. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med 2007; 13: 1241-1247. PubMed
112 Hütter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360: 692-698. PubMed
113 Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013; 369: 1828-1835. PubMed
114 Yukl SA, Boritz E, Busch M, et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog 2013; 9: e1003347. PubMed
115 Li L, Krymskaya L, Wang J, et al. Genomic Editing of the HIV-1 Coreceptor CCR5 in Adult Hematopoietic Stem and Progenitor Cells Using Zinc Finger Nucleases. Mol Ther JAm Soc Gene Ther 2013; 21: 1259-1269. PubMed
116 Sáez-Cirión A, Bacchus C, Hocqueloux L, et althe ANRS VISCONTI Study Group. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9: e1003211. PubMed
117 Lodi S, Meyer L, Kelleher AD, et al. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med 2012; 172: 1252-1255. PubMed
118 Ananworanich J, Schuetz A, Vandergeeten C, et althe RV254/SEARCH 010 Study Group. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One 2012; 7: e33948. PubMed
119 Lewin SR, Rouzioux C. HIV cure and eradication: how will we get from the laboratory to effective clinical trials?. AIDS 2011; 25: 885-897. PubMed
120 Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487: 482-485. PubMed
121 Elliott J, Solomon A, Wightman F, et al. The Safety and Effect of Multiple Doses of Vorinostat on HIV Transcription in HIV+ Patients Receiving cART. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA; 2013. p. 50LB.
122 Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012; 36: 491-501. PubMed
123 Papagno L, Alter G, Assoumou L, et althe ORVACS Study Group. Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. AIDS 2011; 25: 27-36. PubMed
124 Garcia F, Climent N, Guardo AC, et al. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Science Transl Med 2013; 5: 166ra2. PubMed
125 Hansen SG, Piatak M, Ventura AB, et al. Immune clearance of highly pathogenic SIV infection. Nature 2013; 502: 100-104. PubMed
126 Dutta A, Wirtz AL, Baral S, Beyrer C, Cleghorn FR. Key harm reduction interventions and their impact on the reduction of risky behavior and HIV incidence among people who inject drugs in low-income and middle-income countries. Curr Opin HIV AIDS 2012; 7: 362-368. PubMed
127 Kourtis AP, Lee FK, Abrams EJ, Jamieson DJ, Bulterys M. Mother-to-child transmission of HIV-1: timing and implications for prevention. Lancet Infect Dis 2006; 6: 726-732. Summary | Full Text | PDF(168KB) | PubMed
128 BreastfeedingGroup HIVITS, Coutsoudis A, et al. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis 2004; 189: 2154-2166. PubMed
129 de Vincenzi Ithe Kesho Bora Study Group. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11: 171-180. Summary | Full Text | PDF(185KB) | PubMed
130 Thior I, Lockman S, Smeaton LM, et althe Mashi Study Team. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA 2006; 296: 794-805. PubMed
131 Coovadia HM, Brown ER, Fowler MG, et althe HPTN 046 protocol team. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 379: 221-228. Summary | Full Text | PDF(273KB) | PubMed
132 Thomas TK, Masaba R, Borkowf CB, et althe KiBS Study Team. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding--the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med 2011; 8: e1001015. PubMed
133 Wettstein C, Mugglin C, Egger M, et althe IeDEA Southern Africa Collaboration. Missed opportunities to prevent mother-to-child-transmission: systematic review and meta-analysis. AIDS 2012; 26: 2361-2373. PubMed
134 Nachega JB, Uthman OA, Anderson J, et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. AIDS 2012; 26: 2039-2052. PubMed
135 Cohen MS, Chen YQ, McCauley M, et althe HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505. PubMed
136 Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 2013; 339: 966-971. PubMed
137 Coates T, Eshleman S, Chariyalertsak S, et al. Community-level reductions in estimated HIV incidence: HIV Prevention Trials Network 043, Project Accept. 20th Conference on Retroviruses and Opportunistic Infections (CROI). Atlanta, GA; 2013. p. Abstract 30.
138 Sabapathy K, Van den Bergh R, Fidler S, Hayes R, Ford N. Uptake of home-based voluntary HIV testing in sub-Saharan Africa: a systematic review and meta-analysis. PLoS Med 2012; 9: e1001351. PubMed
139 Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52: 793-800. PubMed
140 Sood N, Wagner Z, Jaycocks A, Drabo E, Vardavas R. Test-and-treat in Los Angeles: a mathematical model of the effects of test-and-treat for the population of men who have sex with men in Los Angeles County. Clin Infect Dis 2013; 56: 1789-1796. PubMed
141 Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2: e298. PubMed
142 Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369: 643-656. Summary | Full Text | PDF(193KB) | PubMed
143 Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369: 657-666. Summary | Full Text | PDF(147KB) | PubMed
144 Baeten JM, Donnell D, Ndase P, et althe Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367: 399-410. PubMed
145 Thigpen MC, Kebaabetswe PM, Paxton LA, et althe TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367: 423-434. PubMed
146 Choopanya K, Martin M, Suntharasamai P, et althe Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013; 381: 2083-2090. Summary | Full Text | PDF(229KB) | PubMed
147 Grant RM, Lama JR, Anderson PL, et althe iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363: 2587-2599. PubMed
148 Van Damme L, Corneli A, Ahmed K, et althe FEM-PrEP Study Group. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367: 411-422. PubMed
149 Marrazzo J, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/embricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections (CROI). Atlanta, GA; 2013. p. Abstract 26LB.
150 Abdool Karim Q, Abdool Karim SS, Frohlich JA, et althe CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329: 1168-1174. PubMed
151 Obiero J, Mwethera PG, Hussey GD, Wiysonge CS. Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis. BMC Infect Dis 2012; 12: 289. PubMed
152 Herrera C, Shattock RJ. Candidate Microbicides and Their Mechanisms of Action. Curr Top Microbiol Immunol 2013. [Epub ahead of print].
153 Ball C, Krogstad E, Chaowanachan T, Woodrow KA. Drug-eluting fibers for HIV-1 inhibition and contraception. PLoS One 2012; 7: e49792. PubMed
154 Siegfried N, Muller M, Deeks JJ, Volmink J. Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst Rev 2009; 2. CD003362.
155 Hallett TB, Alsallaq RA, Baeten JM, et al. Will circumcision provide even more protection from HIV to women and men? New estimates of the population impact of circumcision interventions. Sex Transm Infect 2011; 87: 88-93. PubMed
156 Uthman OA, Popoola TA, Yahaya I, Uthman MM, Aremu O. The cost-utility analysis of adult male circumcision for prevention of heterosexual acquisition of HIV in men in sub-Saharan Africa: a probabilistic decision model. Value Health 2011; 14: 70-79. PubMed
157 Ford N, Chu K, Mills EJ. Safety of task-shifting for male medical circumcision: a systematic review and meta-analysis. AIDS 2012; 26: 559-566. PubMed
158 Gray RH, Wawer MJ, Kigozi G. Programme science research on medical male circumcision scale-up in sub-Saharan Africa. Sex Transm Infect 2013; 89: 345-349. PubMed
159 Lorimer K, Kidd L, Lawrence M, McPherson K, Cayless S, Cornish F. Systematic review of reviews of behavioural HIV prevention interventions among men who have sex with men. AIDS Care 2013; 25: 133-150. PubMed
160 Wariki WM, Ota E, Mori R, Koyanagi A, Hori N, Shibuya K. Behavioral interventions to reduce the transmission of HIV infection among sex workers and their clients in low- and middle-income countries. Cochrane Database Syst Rev 2012; 2. CD005272.
161 Kerrigan DL, Fonner VA, Stromdahl S, Kennedy CE. Community empowerment among female sex workers is an effective HIV prevention intervention: a systematic review of the peer-reviewed evidence from low- and middle-income countries. AIDS Behav 2013; 17: 1926-1940. PubMed
162 Kennedy CE, Medley AM, Sweat MD, O'Reilly KR. Behavioural interventions for HIV positive prevention in developing countries: a systematic review and meta-analysis. Bull World Health Organ 2010; 88: 615-623. PubMed
163 Scott-Sheldon LA, Huedo-Medina TB, Warren MR, Johnson BT, Carey MP. Efficacy of behavioral interventions to increase condom use and reduce sexually transmitted infections: a meta-analysis, 1991 to 2010. J Acquir Immune Defic Syndr 2011; 58: 489-498. PubMed
164 Fonner VA, Denison J, Kennedy CE, O'Reilly K, Sweat M. Voluntary counseling and testing (VCT) for changing HIV-related risk behavior in developing countries. Cochrane Database Syst Rev 2012; 9. CD001224.
165 Barnabas RV, Celum C. Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions. Curr HIV Res 2012; 10: 228-237. PubMed
166 Celum C, Wald A, Lingappa JR, et althe Partners in Prevention HSV/HIV Transmission Study Team. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362: 427-439. PubMed
167 Lingappa JR, Baeten JM, Wald A, et althe Partners in Prevention HSV/HIV Transmission Study Team. Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 2010; 375: 824-833. Summary | Full Text | PDF(325KB) | PubMed
168 Mugwanya K, Baeten JM, Mugo NR, Irungu E, Ngure K, Celum C. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial. J Infect Dis 2011; 204: 1912-1917. PubMed
169 Barnabas RV, Webb EL, Weiss HA, Wasserheit JN. The role of coinfections in HIV epidemic trajectory and positive prevention: a systematic review and meta-analysis. AIDS 2011; 25: 1559-1573. PubMed
170 Grosskurth H, Mosha F, Todd J, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 1995; 346: 530-536. Summary | PubMed
171 Ng BE, Butler LM, Horvath T, Rutherford GW. Population-based biomedical sexually transmitted infection control interventions for reducing HIV infection. Cochrane Database Syst Rev 2011; 3. CD001220.
172 Buchbinder SP, Mehrotra DV, Duerr A, et althe Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372: 1881-1893. Summary | Full Text | PDF(278KB) | PubMed
173 Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et althe MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361: 2209-2220. PubMed
174 Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366: 1275-1286. PubMed
175 Haynes BF, McElrath MJ. Progress in HIV-1 vaccine development. Curr Opin HIV AIDS 2013; 8: 326-332. PubMed